Anticoagulant Reversal Drugs Market to Surpass US$ 2,282.7 Million by 2028

Global Anticoagulant Reversal Drugs Market, by Product Type (Idarucizumab, Protamine, Prothrombin Complex Concentrates, Phytonadione, Andexanet Alfa, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 861.6 million in 2021 and is expected to exhibit a CAGR of 14.9% during the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.

Rise in the incidence of indications for anticoagulant therapy is major factor driving the market growth during the forecast period. Anticoagulant therapies are used for certain type indications include atrial fibrillation, coronary artery disease, deep vein thrombosis, ischemic stroke, and pulmonary embolism among others. For instance, in year 2019, about 2% of people under 65 years of age have atrial fibrillation, while 9% of people above 65 years of age have the disease, globally, as per the Centers for Disease Control and Prevention (CDC). Moreover, according to CDC estimates, approximately 12.1 million people are expected to develop atrial fibrillation by 2030.

Global Anticoagulant Reversal Drugs Market– Impact of Coronavirus (COVID-19) Pandemic

Due to the rising pace of research on COVID-19 infection, the global anticoagulant reversal drugs market have positive impact of COVID-19. For instance, according to a study published in the American Journal of Cardiovascular Drugs, in 2020, more than ten clinical trials are in progress to assess the efficacy of factor Xa inhibitors in COVID-19 patients and these medicines parenteral delivery methods are being researched for use in severely sick COVID-19 patients. As a result, the COVID-19 pandemic is likely to have positive effect on the market under consideration.

Browse 20 Market Data Tables and 25 Figures spread through 250 Pages and in-depth TOC on Global Anticoagulant Reversal Drugs Market”- Forecast to 2028, Global Anticoagulant Reversal Drugs Market, by Product Type (Idarucizumab, Protamine, Prothrombin Complex Concentrates, Phytonadione, Andexanet Alfa, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the Global Anticoagulant Reversal Drugs Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/anticoagulant-reversal-drugs-market-4551

Key Takeaways of the Global Anticoagulant Reversal Drugs Market:

• Global anticoagulant reversal drugs market is expected to exhibit a CAGR of 14.9% during the forecast period owing to the global incidence of various cardiovascular indications is increasing, as is the elderly population. For instance, according to the World Health Organization, 17.9 million people die every year as a result of cardiovascular illnesses, accounting for 35% of all mortalities globally. Furthermore, heart attacks and stroke account for 85% of all cardiovascular disease mortalities.
• On the basis of product type, the andexanet alfa segment is expected to grow at a lucrative CAGR during the forecast period due to reimbursement approval of andexanet alfa in major markets. The Centers for Medicare & Medicaid Services (CMS), in April 2020, set a permanent J-code for Andexxa, enabling its reimbursement in the hospital outpatient situations. Therefore a favorable reimbursement state for andexanet alfa in key markets is projected to support the segment growth in the forecast period.
• In terms of distribution channel, the hospital pharmacy segment is highest revenue share of the market. Growing focus of manufacturing industries on supplying anticoagulant reversal drugs to hospital pharmacies over other distribution channels.
• Among regions, North America is expected to exhibit highest CAGR in the global anticoagulant reversal drugs market in 2021, owing to the U.S. acquiring the largest share in the North American anticoagulant reversal drug market. Appropriate healthcare reimbursement programmes and rising healthcare spending on costly medications are the factors driving the market growth. Furthermore, the simplicity with which these reversal medicines may be obtained in an emergency situation also spurring the regional market growth during the forecast period.
• Major players operating in the global anticoagulant reversal drugs market include Portola Pharmaceuticals, Boehringer Ingelheim, CSL Behring, Bausch Health Companies Inc., Octapharma AG, Dr. Reddy's Laboratories, AMAG Pharmaceuticals, Inc., Pfizer, Inc., SGPharma Pvt. Ltd., Alps Pharmaceutical Ind. Co., Ltd., Fresenius Kabi AG, Mundipharma International Limited, and Hisamitsu Pharmaceutical Co., Inc.